Anti-HIV (also called antiretroviral) medications are used to control the
reproduction of the virus and to slow or halt the progression of HIV-related
disease. When used in combinations, these medications are termed Highly Active
Antiretroviral Therapy (HAART). HAART combines three or more anti-HIV medications
in a daily regimen, sometimes referred to as a "cocktail". Anti-HIV medications
do not cure HIV infection and individuals taking these medications can still
transmit HIV to others. Anti-HIV medications approved by the U.S. Food and Drug
Administration (FDA) fall into four classes:
- Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs), such as nevirappine
(Viramune) and efavirenz (Sustiva), bind to and block the action of reverse
transcriptase, a protein that HIV needs to reproduce.
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs), such as zidovudine
(Retrovir), tenofovir DF (Viread), and stavudine (Zerit), are faulty versions
of building blocks that HIV needs to make more copies of itself. When HIV uses
an NRTI instead of a normal building block, reproduction of the virus is stalled.
- Protease Inhibitors (PIs), such as lopinavir/ritonavir (Kaletra), disable
protease, a protein that HIV needs reproduce itself.
- Fusion Inhibitors, such as enfuvirtide (Fuzeon ), are newer treatments that
work by blocking HIV entry into cells.
How many pills you will need to take and how often you will take them
depends on what medications you and your doctor choose.
There is no one "best" regimen. You and your doctor will decide which
medications are right for you. For people taking HAART for the first time, the
recommended regimens are:
- Sustiva + Truvada, Sustiva + Epzicom, or Atripla
- Kaletra + Truvada, Kaletra + Epzicom, or Kaletra + Combivir
In general, taking only one or two drugs is not recommended because any
decrease in viral load is almost always temporary without three or more drugs.
The exception is the recommendation for pregnant women, who may take Combivir
plus nevirapine to reduce the risk of passing HIV to their infants. If you are
pregnant or considering becoming pregnant, there are additional treatment
considerations. Recently, a number of drugs have been developed that combine two
or even three separate medications in a single pill. Some of these, such as
Truvada (emtricitabine + tenofovir) and Epzicom (abacavir + lamivudine) need be
taken only once daily. Atripla (emtricitabine + tenofovir + efavirenz) combines
three drugs in one pill and needs to be taken only once daily, thereby providing
a complete HAART regimen with one pill once daily.
The treatment of HIV infection and AIDS is in a highly dynamic state.
Individuals with this condition are advised to seek out experts in their local
community who are current with the latest modes of therapy and ongoing clinical
trials for evaluating newer therapies.
|